[go: up one dir, main page]

PT1107793E - Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados - Google Patents

Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados

Info

Publication number
PT1107793E
PT1107793E PT99939127T PT99939127T PT1107793E PT 1107793 E PT1107793 E PT 1107793E PT 99939127 T PT99939127 T PT 99939127T PT 99939127 T PT99939127 T PT 99939127T PT 1107793 E PT1107793 E PT 1107793E
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
dextrane
related processes
leptin conjugates
leptin
Prior art date
Application number
PT99939127T
Other languages
English (en)
Inventor
David C Litzinger
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT1107793E publication Critical patent/PT1107793E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/5759Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PT99939127T 1998-08-10 1999-08-10 Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados PT1107793E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9619498P 1998-08-10 1998-08-10
US37068499A 1999-08-09 1999-08-09

Publications (1)

Publication Number Publication Date
PT1107793E true PT1107793E (pt) 2005-02-28

Family

ID=26791397

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99939127T PT1107793E (pt) 1998-08-10 1999-08-10 Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados

Country Status (9)

Country Link
EP (1) EP1107793B1 (pt)
JP (1) JP4199421B2 (pt)
AT (1) ATE280588T1 (pt)
AU (1) AU5347099A (pt)
CA (1) CA2337667C (pt)
DE (1) DE69921486T2 (pt)
ES (1) ES2228082T3 (pt)
PT (1) PT1107793E (pt)
WO (1) WO2000009165A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
JP4841037B2 (ja) * 1999-02-12 2011-12-21 アムジエン・インコーポレーテツド グリコシル化レプチン組成物および関連する方法
GB0116860D0 (en) * 2001-07-10 2001-09-05 Univ Montfort Gel compositions
US20050215710A1 (en) * 2004-03-23 2005-09-29 Gegg Colin V Jr Chemically modified protein compositions and methods
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
WO2010054017A1 (en) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
EA032917B1 (ru) 2010-09-28 2019-08-30 Амилин Фармасьютикалс, Ллк Сконструированные полипептиды, характеризующиеся увеличенной продолжительностью действия
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
SMT201900064T1 (it) 2013-11-26 2019-02-28 Childrens Medical Ct Corp Composti e trattamento dell'obesita' e relativi metodi di uso
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2229450A1 (en) * 1995-08-17 1997-02-27 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
AU2670897A (en) * 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods

Also Published As

Publication number Publication date
JP2002522512A (ja) 2002-07-23
CA2337667A1 (en) 2000-02-24
WO2000009165A1 (en) 2000-02-24
DE69921486T2 (de) 2006-02-02
ATE280588T1 (de) 2004-11-15
ES2228082T3 (es) 2005-04-01
JP4199421B2 (ja) 2008-12-17
AU5347099A (en) 2000-03-06
EP1107793B1 (en) 2004-10-27
CA2337667C (en) 2008-04-29
DE69921486D1 (de) 2004-12-02
EP1107793A1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
AU3652102A (en) Compounds and their uses
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
PT1157037E (pt) Conjugados de gcsf
ATE231872T1 (de) Thiazolopyrimidinderivate
TR200100054T2 (tr) Paroksetin metansülfonat
TR200101412T2 (tr) Yeni bileşikler.
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
SE9801494D0 (sv) Novel use
EA200300727A1 (ru) Производные 2h-1-бензопирана, способы их получения и их фармацевтические композиции
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
SE9803107D0 (sv) Novel Compunds
AR026890A1 (es) Composiciones de tenocitos, preparaciones y utilizaciones
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
IL150979A0 (en) 9-alkylamino-1-nitroacridine derivatives
ES2183543T3 (es) Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica.
SE9803277D0 (sv) Novel compounds